C
Christoph Wanner
Researcher at University of Würzburg
Publications - 7
Citations - 561
Christoph Wanner is an academic researcher from University of Würzburg. The author has contributed to research in topics: Kidney disease & Fabry disease. The author has an hindex of 7, co-authored 7 publications receiving 440 citations.
Papers
More filters
Journal ArticleDOI
Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival - an analysis of data from the ERA-EDTA Registry
Edwin M. Spithoven,Anneke Kramer,Esther Meijer,Bjarne Orskov,Christoph Wanner,Jose M. Abad,Nuria Areste,Ramón Alonso de la Torre,Fergus Caskey,Cécile Couchoud,Patrik Finne,James G. Heaf,Andries J. Hoitsma,Johan De Meester,Julio Pascual,Maurizio Postorino,Pietro Ravani,Oscar Zurriaga,Kitty J. Jager,Ron T. Gansevoort,Era-Edta Registry,Wgikd +21 more
TL;DR: In ADPKD patients on RRT, survival has improved markedly, especially due to a decrease in cardiovascular mortality, which has led to a considerable increase in the number of AD PKD patients being treated with RRT.
Journal ArticleDOI
The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts.
Dominique P. Germain,Perry M. Elliott,Bruno Falissard,Victor Fomin,Max J. Hilz,Ana Jovanovic,Ilkka Kantola,Aleš Linhart,Renzo Mignani,Mehdi Namdar,Albina Nowak,João Paulo Oliveira,Maurizio Pieroni,Miguel Viana-Baptista,Christoph Wanner,Marco Spada +15 more
TL;DR: A comprehensive systematic literature review of all original articles on Enzyme Replacement Therapy (ERT) in the treatment of Fabry disease published up until January 2017 is presented in adult male patients.
Journal ArticleDOI
Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease
Edwin M. Spithoven,Anneke Kramer,Esther Meijer,Bjarne Orskov,Christoph Wanner,Fergus Caskey,Frederic Collart,Patrik Finne,Damian G. Fogarty,Damian G. Fogarty,Jaap W. Groothoff,Andries J. Hoitsma,Marie-Béatrice Nogier,Maurizio Postorino,Pietro Ravani,Oscar Zurriaga,Kitty J. Jager,Ron T. Gansevoort +17 more
TL;DR: No change over time was found in the incidence of RRT for ADPKD up to age 50, whereas in recent time periods the incidence in patients above the age of 70 clearly increased, and among countries there was a significant positive association between RRT take-on rates for non-ADPKD kidney disease and AD PKD.
Journal ArticleDOI
Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice
Wim Terryn,Pierre Cochat,Roseline Froissart,Alberto Ortiz,Yves Pirson,Bruce Poppe,Andreas L. Serra,Wim Van Biesen,Raymond Vanholder,Christoph Wanner +9 more
TL;DR: It is unclear whether enzyme replacement therapy (ERT) prevents deterioration of kidney function, and the low likelihood that a sufficiently powered randomized controlled trial on this topic will be performed, data of all patients with FD should be collected in a central registry.
Journal ArticleDOI
Mild cognitive impairment and kidney disease: clinical aspects
Davide Viggiano,Carsten A. Wagner,Peter J. Blankestijn,Annette Bruchfeld,Danilo Fliser,Denis Fouque,Sebastian Frische,Loreto Gesualdo,Eugenio Gutierrez,Dimitrios S. Goumenos,Ewout J. Hoorn,Kai-Uwe Eckardt,Samuel Knauß,Maximilian König,Jolanta Malyszko,Ziad A. Massy,Dorothea Nitsch,Francesco Pesce,Ivan Rychlik,María José Soler,Goce Spasovski,Kathryn Stevens,Francesco Trepiccione,Christoph Wanner,Andrzej Wiecek,Carmine Zoccali,Robert J. Unwin,Robert J. Unwin,Giovambattista Capasso +28 more
TL;DR: Brain imaging and electrophysiological studies suggest that MCI-CKD represents a more complex clinical entity different in many ways from MCI seen in the general population, which is more often age-related and linked to widespread vascular disease.